Pregnancy in MS.

Slides:

Advertisements

Similar presentations

Moderate-to-Severe Asthma Management

Advertisements

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Systemic Lupus Erythematosus

Clinical Trials in IBD.

New Psoriasis Treatments

A Review of the Critical Role of Imaging in Primary Liver Malignancy

Highlights From the 2017 Annual European MS Meeting

Why Gene Therapy for Hemophilia?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

Why Treat Seborrheic Keratosis?

Improving Acne Outcomes

Case Challenges in Chronic Migraine

Advances in Dry Eye.

Before and After: Patient Cases in Onychomycosis

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Issues in the Management of Hemophilia: A Best Practice Series

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Treat to Target in Gout.

Treating Transplant-Ineligible Patients With Multiple Myeloma

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Asthma and Atopic Comorbidities

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

Gene Therapy: Past, Present, and Future

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Charting Progress in MS Treatment:

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

Treating to Target in MS

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

How to Select Therapy In Newly Diagnosed CLL

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Program Goals Overview Is NEDA a Reasonable Target?

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

The Psychiatrist's Role in Tardive Dyskinesia

Program Goals Overview Is NEDA a Reasonable Target?

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Pregnancy in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US.

MS and Pregnancy: Pregnancy Is Not a Negative Prognostic Indicator

When Should DMTs Be Started in a Young Treatment-Naive Woman Who Wants to Become Pregnant?

Primary Progressive MS

MS ≠ High-Risk Pregnancy

Treating Relapse During Pregnancy

Is DMT Washout Necessary Before Considering Conception?

DMT Use During Pregnancy

Covering Medication Gaps: Bridging Strategies

Long-Lasting Induction Therapies: Pregnancy Planning

Abbreviations